Alterity Therapeutics (ASX:ATH) Presentation, FNN Investor Event, June 2019, Sydney

Company Presentations

Alterity Therapeutics Limited (ASX:ATH) CEO & Chairman, Geoffrey Kempler, presents on the company's lead drug candidate, the potential applications for the drug and the breadth of the market at FNN's Investor Event.

Key points:

  • Share price up approx 3 per cent year to date.
  • Dual-listed company formerly known as Prana Biotechnology.
  • Lead drug has orphan drug status for the treatment of Multiple System Atrophy.
  • Strong leadership team with proven track record obtaining US FDA approvals.

For more, watch CEO and Chairman, Geoffrey Kempler present